Insulin long-acting (HM 12460A) - Hanmi Pharmaceutical
Alternative Names: HM 12460A; HM 12460B; LAPS-Insulin - Hanmi Pharmaceutical; LAPSInsulin; Ultra-Long Acting Insulin - Hanmi PharmaceuticalLatest Information Update: 04 Apr 2022
Price :
$50 *
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 04 Apr 2022 Discontinued - Phase-I for Type 1 diabetes mellitus (In volunteers) in USA (IV) (Hanmi Pharmaceutical pipeline, April 2022)
- 04 Apr 2022 Discontinued - Phase-I for Type 1 diabetes mellitus in USA (SC) (Hanmi Pharmaceutical pipeline, April 2022)
- 04 Apr 2022 Discontinued - Phase-I for Type 2 diabetes mellitus (In volunteers) in USA (IV) (Hanmi Pharmaceutical pipeline, April 2022)